Results 201 to 210 of about 16,733 (229)

Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.

Lancet. Infectious Diseases (Print)
BACKGROUND There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive REVISIT study, we investigated the safety and efficacy of aztreonam-avibactam in the treatment of ...
Y. Carmeli, J. M. Cisneros, Mical Paul, George L. Daikos, Minggui Wang, J. Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa M Jimenez-Rodriguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley Rogers, M. Wible, Francis F Arhin, Alison Luckey, Joanne Leaney, Rienk Pypstra, Joseph W Chow   +21 more
semanticscholar   +1 more source

Aztreonam-avibactam for the treatment of intra-abdominal infections

Expert Opinion on Pharmacotherapy
Intra-abdominal infections are becoming increasingly common and can lead to significant morbidity and mortality. The incidence of these infections due to resistant gram-negative organisms is also increasing. Given this resistance, new antibiotic combinations are being developed, often utilizing older antibiotics and newer β-lactamase inhibitors ...
Hannah Delp, Gabrielle A. Gibson, Sara A. Buckman   +2 more
openaire   +2 more sources

Geographic variations in distributions of carbapenemase-encoding genes, susceptibilities, and minimum inhibitory concentrations of inpatient meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam across four global regions: 2020-2022 Data from t

International Journal of Antimicrobial Agents
To evaluate the susceptibility profiles of regional inpatient meropenem-resistant (MEM-R) carbapenemase-producing Enterobacterales (CPE) isolates and their MIC values to ceftazidime-avibactam (CZA), meropenem-vaborbactam (MVB), and aztreonam-avibactam ...
S. Jean, Chih-Cheng Lai, Sung-Jung Ho, I. Liu, Po-Chuen Hsieh, P. Hsueh   +5 more
semanticscholar   +1 more source

Resistance of Gram-negative bacteria to aztreonam-avibactam: An evaluation of data from in vitro studies.

International Journal of Antimicrobial Agents
INTRODUCTION Aztreonam-avibactam is a new combination antibiotic with a broad spectrum of activity against Enterobacterales and lactose non-fermenting Gram-negative bacteria.
Matthew E. Falagas, Laura T. Romanos, Dimitrios S. Kontogiannis, Charalampos Filippou   +3 more
semanticscholar   +1 more source

Aztreonam-avibactam resistance rates and resistance mechanisms of NDM and NDM/OXA48-like dual-carbapenemase-producing Enterobacterales in Singapore.

Pathology (Sydney)
Aztreonam-avibactam is a treatment option for metallo-β-lactamase carbapenemase-producing Enterobacterales (CPE). This study was performed to determine resistance rates of a collection of CPE against aztreonam-avibactam and characterise associated ...
K. Chew, Joey Cruz Cabang, Nur Aisyah Binte Abu Bakar, Ker Xin Tan, J. Teo   +4 more
semanticscholar   +1 more source

A Selective Culture Medium for Screening Aztreonam-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa

Microbial Drug Resistance
Aztreonam/avibactam (ATM/AVI) has been recently approved drug for clinical use in the European Union. The aim of this study was to develop and evaluate a novel selective medium for the isolation of ATM/AVI-resistant strains (Super ATM/AVI selective medium) to help to control their spread.
Herrera-Espejo, Soraya, Bouvier, Maxime, Cordero, Elisa, Poirel, Laurent, Pachón-Ibáñez, M. E., Nordmann, Patrice   +5 more
openaire   +3 more sources

Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates.

Diagnostic microbiology and infectious disease
In recent years, novel β-lactam-inhibitor combinations (imipenem-relebactam (I/R), meropenem-vaborbactam (M/V), aztreonam-avibactam (A/A)) have been commercialized and some are not yet on the market (cefepime-zidebactam (C/Z)).
C. Petillon, Mauli Ululuipalelei, R. Beyrouthy, S. Proust, Nejla Aissa, L. Bret, Nathalie Brieu, A. Carricajo, Vincent Cattoir, Olivier Dauwalder, N. Degand, L. Dortet, Florence Doucet-Populaire, Véronique Dubois, Antoine Grillon, F. Guérin, Philippe Lanotte, Nadine Lemaître, D. Leyssene, Catherine Neuwirth, I. Patry, M. Ploy, Isabelle Podglajen, C. Recule, Karama Rouis, Onerba Réseau, Jérôme Robert, R. Bonnet, F. Robin   +28 more
semanticscholar   +1 more source

Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan.

International Journal of Infectious Diseases
OBJECTIVES To evaluate susceptibilities of novel antibiotics against imipenem-non-susceptible Escherichia coli (INS-EC), Klebsiella pneumoniae (INS-KP), Acinetobacter baumannii (INS-AB), Pseudomonas aeruginosa (INS-PA) in Taiwan, and the potential ...
Yan-Ru Wang, Yu-Lin Lee, Mei-Chen Tan, Pei-Jing Chen, I-Wen Huang, Jui-Fen Lai, Hui-Ying Wang, Y. Shiau, Shu-Chen Kuo, Ya-Sung Yang   +9 more
semanticscholar   +1 more source

Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing

Journal of Antimicrobial Chemotherapy, 2023
Manon Deschamps, Ollivier Dauwalder, Laurent Dortet   +2 more
openaire   +2 more sources

[Role of aztreonam/avibactam in antibiotic therapy].

Klinicka mikrobiologie a infekcni lekarstvi
The article reviews current options for the treatment of infections caused by carbapenemase-producing Enterobacterales, including the role of aztreonam/avibactam.
openaire   +1 more source